Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A - Dent, R; Kim, S-B; Oliveira, M (San Antonio Breast Cancer Symposium, 2020)
Accessed March 16 2021 at: